Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$122.84 USD

122.84
1,000,340

-2.16 (-1.73%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $122.86 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Sarepta Therapeutics (SRPT) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Sarepta's (SRPT) Q3 earnings and sales beat estimates on the back of strong sales for recently approved DMD gene therapy Elevidys.

Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up

by Zacks Equity Research

Lisata (LSTA) shares rise 6.6% after its lead candidate, LSTA1, receives orphan drug designation from the European Commission for treating pancreatic cancer.

Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD

by Zacks Equity Research

The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickle cell disease. Shares rise.

AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.

Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B

by Zacks Equity Research

Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.

Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse

by Zacks Equity Research

The FDA accepts Catalyst's (CPRX) sNDA to increase the indicated maximum daily dosage of Firdapse 10 mg from 80mg to 100mg for treating Lambert-Eaton myasthenic syndrome. The decision is due on Jun 4, 2024.

Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering

by Zacks Equity Research

Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.

Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now

by Zacks Equity Research

Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.

Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.6%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 50.6% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody

by Zacks Equity Research

Coherus (CHRS) resubmits biologics license application for Udenyca Onbody, an on-body injector presentation of Udenyca to the FDA. Stock rises.

Sarepta Therapeutics (SRPT) Up 12.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Quest Diagnostics' (DGX) AAV Test Gets FDA's Breakthrough Nod

by Zacks Equity Research

Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.

FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%

by Zacks Equity Research

FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.

Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 85.71% and 1.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.

Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.

Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta (SRPT) Sells Priority Review Voucher for $102M

by Zacks Equity Research

Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.

Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates

by Zacks Equity Research

Regulatory updates from Sarepta (SRPT) and Intercept (ICPT) are in focus in the biotech sector.

Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy

by Zacks Equity Research

Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.